Trutakna Statistics in US 2026 | IgA Nephropathy, FDA Approval & Facts

Trutakna in United States 2026

Kidney disease treatment in America just reached a genuine milestone. On July 7, 2026, the FDA granted accelerated approval to Trutakna (atacicept-vymj), developed by Vera Therapeutics, making it the first and only approved therapy that targets both B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) — the two upstream immune proteins believed to drive IgA nephropathy (IgAN), the most commonly diagnosed primary glomerular kidney disease in American adults. For a condition that has quietly affected somewhere between 100,000 and 200,000-plus Americans without a treatment addressing its root immunological cause, this approval represents a meaningful shift from managing symptoms to intervening earlier in the disease process itself.

What makes Trutakna’s arrival particularly significant is both the strength of its clinical trial data and the practical design of the treatment itself. Backed by results from the ongoing ORIGIN 3 trial, the drug is delivered as a once-weekly, at-home subcutaneous injection via autoinjector, putting it in a category of convenience that matters enormously for a chronic disease often diagnosed in younger and middle-aged adults who need long-term management rather than repeated clinic visits. This article brings together the latest verified 2026 US data on Trutakna’s approval, its trial results, IgA nephropathy prevalence nationwide, and what the accelerated approval pathway actually means for patients and prescribers going forward.

Trutakna Facts 2026

Source: Vera Therapeutics FDA announcement, ORIGIN 3 trial data, PMC national IgAN incidence/prevalence study

The 46% reduction in proteinuria from baseline, backed by a statistically significant 42% reduction compared with placebo, is the core clinical result behind Trutakna’s accelerated approval, and it matters because proteinuria is the surrogate endpoint the FDA is using to justify early access to a therapy for a slow-progressing but ultimately serious kidney disease. The 68% reduction in Gd-IgA1, a biomarker tied directly to the disease’s underlying pathophysiology, adds mechanistic weight to the proteinuria data, since it shows the drug isn’t just masking symptoms but affecting the actual immune process believed to drive kidney damage in IgA nephropathy.

On the epidemiological side, the range in the estimated 198,887 to 208,184 Americans living with IgAN reflects how difficult this disease is to precisely count, since diagnosis requires an invasive kidney biopsy rather than a simple blood test, meaning the true number of cases is very likely underreported. The fact that 20% to 50% of patients eventually progress to kidney failure over a 20-to-30-year window underscores why a therapy addressing the disease’s immune drivers, rather than just slowing progression after the fact, has been such a long-anticipated development in American nephrology.

IgA Nephropathy Prevalence Statistics US 2026

Source: PMC “Incidence and Prevalence of Immunoglobulin A Nephropathy in the United States,” national pathologist survey and claims database study

The most rigorous recent national estimate for IgA nephropathy in the US comes from a study combining a pathologist survey with insurance claims data, which found an annual incidence of 2.1 to 2.2 cases per 100,000 people, translating to a total national prevalence of roughly 198,887 to 208,184 Americans when extrapolated across the population in 2021. A separate validation analysis using electronic health records found a somewhat lower incidence of 1.9 per 100,000 and prevalence of 54.2 per 100,000, illustrating how much estimates can shift depending on the dataset and methodology used, but all converging on IgAN being a genuinely widespread, if under-recognized, kidney condition.

Older meta-analyses of the broader research literature found a lower annual incidence estimate of 1.29 per 100,000, translating to roughly 4,236 new adult and pediatric cases diagnosed annually in the US, while separate estimates place the total number of biopsy-confirmed cases at approximately 100,000 — notably lower than the roughly 350,000 biopsy-confirmed cases estimated in Japan, where IgAN is far more common due to genetic and possibly dietary factors. This variation across studies is a direct consequence of how the disease is diagnosed: because a kidney biopsy is required for confirmation, and biopsy practices vary enormously by hospital, region, and clinician judgment, researchers broadly agree that published figures likely undercount the true number of Americans living with the condition.

IgA Nephropathy Regional and Demographic Statistics US 2026

Source: Kaiser Permanente Southern California Department of Research & Evaluation; systematic review of US IgAN incidence by race and ethnicity

Regional variation in reported IgA nephropathy incidence across the US is substantial, ranging from as low as 0.39 per 100,000 in Tennessee to 1.4 per 100,000 in Minnesota, according to a systematic review of published state-level studies. A more recent Kaiser Permanente Southern California study, using the racially and ethnically diverse population of that region as a sample and standardizing findings against 2020 US Census demographics, arrived at an overall national estimate of 1.4 cases per 100,000 person-years, closely matching the Minnesota figure and suggesting that earlier lower estimates in less diverse regions may partly reflect underlying demographic composition rather than true differences in disease biology.

That same Kaiser Permanente research found that Asian/Pacific Islander and Hispanic patients had the highest incidence rates of IgAN within the studied population, a finding broadly consistent with the disease’s well-documented global skew toward higher rates in Asian populations, where the international incidence range climbs as high as 4.2 per 100,000 in Japan compared with a low of 0.06 per 100,000 in South Africa. Notably, a separate systematic review of the specific Black-versus-White comparison within the US found no consistent difference in incidence between those two groups across the studies reviewed, indicating that ethnicity-linked incidence patterns in IgAN are more nuanced than a simple racial binary and instead cluster more specifically around Asian and Hispanic demographic groups. For a broader look at how kidney disease staging and progression are tracked across the wider US patient population, the Chronic Kidney Disease Stages Statistics in US report covers how conditions like IgAN fit into the larger national CKD picture.

Trutakna Clinical Trial Results US 2026

Source: Vera Therapeutics ORIGIN 3 trial data; BioPharm International clinical trial coverage

The ORIGIN 3 trial results underpinning Trutakna’s accelerated approval are notable not just for their statistical strength but for their consistency across every prespecified patient subgroup the researchers examined, including age, sex, race, region, baseline proteinuria level, baseline kidney function (eGFR), and whether patients were already taking an SGLT2 inhibitor. This broad consistency matters clinically because it suggests the drug’s proteinuria-lowering effect isn’t concentrated in a narrow slice of patients but applies fairly uniformly across the kind of diverse patient population that actually presents with IgA nephropathy in real-world US nephrology clinics.

Because Trutakna received accelerated approval based on the proteinuria surrogate endpoint rather than confirmed long-term kidney function preservation, the trial continues in a placebo-controlled, blinded manner, with the critical confirmatory data on kidney function decline, measured via estimated glomerular filtration rate (eGFR), expected in the third quarter of 2026. Vera Therapeutics has indicated a supplemental Biologics License Application submission is targeted for the fourth quarter of 2026, meaning the drug’s continued approval status will hinge on whether that eGFR data confirms the proteinuria benefit translates into genuine long-term protection against kidney function decline — a distinction that’s central to understanding what an accelerated approval actually guarantees versus what remains to be proven.

Trutakna Safety and Administration Statistics US 2026

Source: BioPharm International, “FDA Grants Accelerated Approval to Trutakna as First BAFF and APRIL Inhibitor for IgA Nephropathy”

Trutakna’s safety profile from the registrational trial population of 428 patients shows the drug was generally well tolerated, with the most common adverse reactions being infections, occurring in 32% of Trutakna patients versus 28% on placebo, and local injection-site reactions, occurring in 30% versus just 5% on placebo. That roughly six-fold difference in injection-site reactions is unsurprising for a weekly self-administered subcutaneous biologic, and importantly, the majority of these reactions were described as mild or moderate and resolved without requiring treatment interruption, an important reassurance for patients considering a long-term weekly regimen.

Perhaps the most clinically reassuring safety finding is that no serious, severe, or opportunistic infections and no cases of hypogammaglobulinemia were observed in the Trutakna group during the trial, a meaningful distinction given that the drug works by suppressing specific B-cell signaling pathways, which in theory could raise broader immune-suppression concerns. The once-weekly, 150 mg subcutaneous dose delivered via autoinjector for at-home self-administration was designed specifically to reduce the treatment burden compared with infusion-based biologics that require regular clinic visits, a practical advantage for a patient population that skews toward younger and middle-aged adults managing a chronic condition over years or decades. Because IgAN sits within the broader category of immune-mediated kidney conditions, the mechanisms Trutakna targets connect to research explored more broadly in the Autoimmune Diseases Statistics in US report, which covers how B-cell and antibody-driven pathways are increasingly being targeted across a range of American autoimmune conditions.

IgA Nephropathy Disease Burden Statistics US 2026

Source: US Renal Data System 2013; Efficacy and Safety of Atacicept in IgA Nephropathy clinical trial background data

Historical data from the US Renal Data System shows that IgAN accounted for 1.8%, or 10,557 patients, of all prevalent dialysis subjects as of the end of 2011, with roughly 1,000 new dialysis-dependent IgAN patients added annually during the 2007-2011 study period. Translated into a national rate, this works out to an annual incidence of end-stage renal disease attributable to IgAN of approximately 0.32 per 100,000 people, a figure that, while numerically small, represents a steady and largely preventable stream of patients reaching kidney failure from a single underlying disease.

This is precisely the disease trajectory that Trutakna and the broader wave of new IgAN therapies are designed to interrupt: since 20% to 50% of patients historically progress to kidney failure within 20 to 30 years of diagnosis, a therapy capable of meaningfully reducing proteinuria early in the disease course has the potential to prevent a meaningful share of those dialysis cases from ever occurring, assuming the confirmatory eGFR data due later in 2026 validates that connection. Because dialysis and transplant remain the ultimate downstream consequence of unmanaged IgAN, the broader context of how the US healthcare system tracks and funds treatment for uncommon, progressive conditions like this one connects closely to the themes explored in the Rare Diseases Statistics in US report, which looks at diagnostic delay, treatment access, and the economic burden facing patients with conditions that fall outside the most commonly funded disease categories.

What the historical dialysis data also underscores is how long the gap has been between diagnosing IgAN and having a therapy that addresses its immunological cause rather than simply managing its downstream kidney damage. For decades, standard treatment for IgA nephropathy in the US has centered on blood pressure control, ACE inhibitors or ARBs to reduce proteinuria indirectly, and more recently SGLT2 inhibitors, none of which target the B-cell activating factor and APRIL pathways now understood to sit upstream of the disease process. Trutakna’s approval alongside other emerging mechanisms, including APRIL-only inhibitors currently in development, signals that 2026 marks a genuine turning point in how nephrologists think about treating this disease at its immunological source rather than only at its clinical consequences.

That shift also has implications for how the roughly 200,000 or more Americans currently estimated to be living with IgAN might be identified and treated going forward. Because diagnosis still requires an invasive kidney biopsy, a large share of people with mild or early-stage disease likely remain undiagnosed, meaning the true addressable patient population for a therapy like Trutakna could be considerably larger than current prevalence figures suggest. As awareness of accelerated-approval biologics targeting BAFF and APRIL grows among primary care physicians and general nephrologists, earlier referral for biopsy confirmation and earlier treatment initiation could meaningfully change the disease’s long-term trajectory for patients who might otherwise have gone undetected until later, more advanced stages of kidney damage.

Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE